The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q1 2017 call → NOThe question asks whether management conveys that the reported results for the period do not represent the business the company is actually running today — that is, whether management indicates the reported period is stale relative to the operating present. Looking at the transcript, several elements stand out: 1. SPINRAZA launch: "Biogen reported sales of SPINRAZA of over $47 million in the first quarter" — this is the first full quarter of commercial revenue. The company recognized $5.2 million in commercial revenue from SPINRAZA royalties in Q1. 2. The company received $75 million from Bayer, $175 million from Novartis collaboration — these are new deals. 3. The company is preparing for volanesorsen launch in 2018, IONIS-TTRRx Phase III data imminent. 4. Beth Hougen's comments: "Q1 was the first full quarter in which we added commercial revenues to our substantial base of R&D revenue" — this suggests the commercial revenue stream is just beginning. 5. The company filed for Akcea IPO. 6. The company's financial guidance: "We're on track to meet our 2017 financial guidance of being breakeven or profitable at the operating line on a pro forma basis and a cash balance of more than $825 million." Now, does management convey that the reported period is stale relative to the operating present? Let me look for specific language about the gap between the reported period and current business. Key quotes: - "2017 is off to a great start" — Stan Crooke - "The addition of commercial revenue from SPINRAZA is a reflection of the evolution of our business and our progress towards sustained profitability" — Beth - "We're now closer than ever to our goal of becoming a profitable multiproduct company" — Stan The company is transitioning from R&D revenue to commercial revenue. The Q1 results include the first full quarter of SPINRAZA commercial revenue. The company is describing a transition to a multiproduct profitable organization. However, is management saying the reported numbers are stale relative to what's happening now? The company is describing a transition, but the reported period already includes the new commercial revenue. The company is describing its current state as being in transition, but the reported period reflects that transition beginning. Let me think about this more carefully.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.